Charles A. McWherter
2022
In 2022, Charles A. McWherter earned a total compensation of $1.2M as President of R&D at Cymabay Therapeutics, a 8% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $240,000 |
|---|---|
| Option Awards | $525,465 |
| Salary | $456,685 |
| Other | $3,963 |
| Total | $1,226,113 |
McWherter received $525.5K in option awards, accounting for 43% of the total pay in 2022.
McWherter also received $240K in non-equity incentive plan, $456.7K in salary and $4K in other compensation.
Rankings
In 2022, Charles A. McWherter's compensation ranked 2,637th out of 5,760 executives tracked by ExecPay. In other words, McWherter earned more than 54.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,637 out of 5,760 | 54th |
Division Manufacturing | 1,462 out of 3,136 | 53rd |
Major group Chemicals And Allied Products | 668 out of 1,422 | 53rd |
Industry group Drugs | 621 out of 1,323 | 53rd |
Industry Pharmaceutical Preparations | 448 out of 969 | 54th |
Source: SEC filing on April 19, 2023.
McWherter's colleagues
We found two more compensation records of executives who worked with Charles A. McWherter at Cymabay Therapeutics in 2022.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019